Skip to content
PIL Logo

Glimepiride 1/2/3/4 mg Tablets

Last Updated on eMC 05-Aug-2014 View document  | Accord Healthcare Limited Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 05-Aug-2014 and displayed until Current

Reasons for adding or updating:

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision
  • Change to section 2 - use in children/adolescents

Updated on 27-Feb-2014 and displayed until 05-Aug-2014

Reasons for adding or updating:

  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - date of revision

Updated on 23-Sep-2013 and displayed until 27-Feb-2014

Reasons for adding or updating:

  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 5 - how to store

Updated on 06-Feb-2012 and displayed until 23-Sep-2013

Reasons for adding or updating:

  • New PIL for eMC ie a PIL for an existing product but one that is new to the eMC

Company contact details

Accord Healthcare Limited

Company image
Address

Sage House, 319 Pinner Road, North Harrow, Middlesex, HA1 4HF, UK

Fax

+44 (0)208 861 4867

Medical Information e-mail
Medical Information Fax

+44 (0)208 861 4867

Telephone

+44 (0)208 8631 427

Medical Information Direct Line

+44 (0)208 901 3370

Customer Care direct line

+44 (0)208 863 1427

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

glimepiride

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue